TESARO, Inc. (TSRO) Rating Reiterated by Cowen and Company

TESARO, Inc. (NASDAQ:TSRO)‘s stock had its “hold” rating restated by stock analysts at Cowen and Company in a report issued on Thursday, May 11th. They presently have a $145.00 price objective on the biopharmaceutical company’s stock. Cowen and Company’s price target indicates a potential upside of 0.48% from the company’s previous close.

The analysts wrote, “TSRO reported 1Q financials, provided a pipeline update and commented on Zejula’s.””

Other equities analysts have also issued research reports about the company. Leerink Swann lowered TESARO from an “outperform” rating to a “market perform” rating and set a $186.00 price objective on the stock. in a research note on Friday, February 10th. They noted that the move was a valuation call. Wedbush boosted their target price on TESARO from $164.00 to $174.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 28th. Citigroup Inc. restated a “buy” rating and set a $216.00 target price (down previously from $232.00) on shares of TESARO in a research report on Saturday, April 22nd. FBR & Co downgraded TESARO from an “outperform” rating to a “market perform” rating and boosted their target price for the stock from $151.00 to $202.00 in a research report on Thursday, February 16th. Finally, Robert W. Baird dropped their target price on TESARO from $182.00 to $165.00 and set a “positive” rating for the company in a research report on Wednesday, March 15th. Nine equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $174.32.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

TESARO (NASDAQ:TSRO) opened at 144.31 on Thursday. The firm’s market capitalization is $7.77 billion. The stock’s 50 day moving average price is $145.90 and its 200-day moving average price is $151.16. TESARO has a one year low of $36.71 and a one year high of $192.94.

TESARO (NASDAQ:TSRO) last posted its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($2.55) EPS for the quarter, missing analysts’ consensus estimates of ($2.26) by $0.29. The business had revenue of $3.10 million during the quarter, compared to analyst estimates of $3.84 million. TESARO had a negative return on equity of 96.49% and a negative net margin of 910.35%. TESARO’s revenue for the quarter was up 909.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($2.22) EPS. On average, equities research analysts anticipate that TESARO will post ($8.74) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.com-unik.info/2017/06/17/tesaro-inc-tsro-earns-hold-rating-from-cowen-and-company-updated-updated-updated.html.

In other TESARO news, SVP Martin H. Jr. Huber sold 829 shares of the stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $153.02, for a total value of $126,853.58. Following the completion of the sale, the senior vice president now directly owns 6,522 shares in the company, valued at $997,996.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Edward C. English sold 8,500 shares of the stock in a transaction dated Tuesday, June 6th. The stock was sold at an average price of $138.65, for a total value of $1,178,525.00. Following the completion of the sale, the vice president now owns 5,396 shares of the company’s stock, valued at $748,155.40. The disclosure for this sale can be found here. Corporate insiders own 40.50% of the company’s stock.

Several large investors have recently made changes to their positions in TSRO. SG Americas Securities LLC increased its stake in shares of TESARO by 37.3% in the third quarter. SG Americas Securities LLC now owns 4,667 shares of the biopharmaceutical company’s stock valued at $468,000 after buying an additional 1,267 shares during the period. BlackRock Institutional Trust Company N.A. increased its stake in shares of TESARO by 7.2% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 770,929 shares of the biopharmaceutical company’s stock valued at $77,278,000 after buying an additional 51,632 shares during the period. Rhumbline Advisers increased its stake in shares of TESARO by 14.7% in the third quarter. Rhumbline Advisers now owns 28,395 shares of the biopharmaceutical company’s stock valued at $2,846,000 after buying an additional 3,636 shares during the period. TIAA CREF Investment Management LLC increased its stake in shares of TESARO by 4.7% in the third quarter. TIAA CREF Investment Management LLC now owns 89,979 shares of the biopharmaceutical company’s stock valued at $9,019,000 after buying an additional 4,071 shares during the period. Finally, Teachers Advisors LLC increased its stake in shares of TESARO by 6.0% in the third quarter. Teachers Advisors LLC now owns 45,613 shares of the biopharmaceutical company’s stock valued at $4,572,000 after buying an additional 2,588 shares during the period.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

What are top analysts saying about TESARO Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for TESARO Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit